Abstract 56P
Background
Palbociclib has been the first and only CDK4/6 inhibitor approved for breast cancer treatment by China Food and Drug Administration since July 2018. This research concluded the clinical use of palbociclib and provided stratified analyses by indicators that have not been reported, such as weight, percentage of estrogen receptor (ER) plus progesterone receptor (PR), and time to re-biopsy.
Methods
We retrospectively analyzed data from breast cancer patients treated with palbociclib and endocrine therapy from our medical center between May 2018 and January 2020.
Results
Among 51 patients treated with palbociclib, 14 patients were treated in first-line and 37 patients in second or later lines with a median progression-free survival (PFS) of 8 months (95% CI: 5.05-10.96), while the median PFS of first-line patients has not reached. Median PFS of all groups was 10 months (95%CI: 7-13). Patients with recent immunohistochemical confirmation 6 months before had a median PFS of 8 months (95% CI: 5.24-10.79) and group with pathology in 6 months had not reached its mPFS. Non-hepatic metastatic patients had a median PFS of 11 months (95% CI: 9.00-13.00), while the hepatic metastatic ones of 3 months (95% CI: 0.95-5.05). The objective response rate (ORR) was 10.6% (5/47, 95% confidence interval [CI]: 3.5%-23.1%) and clinical benefit rate (CBR) was 67.4% (29/43, 95% CI: 51.5%-80.9%). Better clinical outcomes were associated with recent pathological confirmation of immunohistochemical analysis (P=0.046) and non-hepatic metastasis (P=0.001), but they were not related to ER/PR percentage, Ki67 index, weight, or previous chemotherapy in first/second line of palbociclib setting groups.
Conclusions
Our report indicated favorable efficacy of palbociclib in terms of recent pathological confirmation and non-hepatic metastasis, providing further information about the use of palbociclib.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
244P - Optimization of early diagnostics of cervical intraepitelial neoplasies and cervical cancer
Presenter: Zakhirova Nargiza
Session: e-Poster Display Session
245P - Clinicopathological features including response to platinum-based chemotherapy in endometrial carcinomas involving SWI/SNF complex inactivation.
Presenter: Izumi Tanimoto
Session: e-Poster Display Session
246P - Impact of genetically predicted elevated concentrations of C-reactive protein on ovarian cancer risk: A Mendelian randomization study
Presenter: Haoxin Peng
Session: e-Poster Display Session
247P - The role of p53 gene suppressor and bcl-2 oncoprotein in non-epithelial ovarian tumor prognosis determination among child and adolescent patients
Presenter: Anvar Shukullaev
Session: e-Poster Display Session
248P - The effect of progesterone on ALA-based PDT efficacy in uterine sarcoma cells
Presenter: Ellie Chu
Session: e-Poster Display Session
249P - A Retrospective Study on the Treatment Response of Locally Advanced Cervical Cancer Patients to Combination Chemoradiotherapy
Presenter: Siti Nabihah Sahralidin
Session: e-Poster Display Session
250P - Health-related Quality of Life in Women with Cervical Cancer
Presenter: Almagul Zhabagina
Session: e-Poster Display Session
251P - Tendency of morbidity and mortality in cervical cancer in the last 10 years in the Republic of Uzbekistan
Presenter: Mirzagaleb Tillyashaykhov
Session: e-Poster Display Session
252P - Secondary data analysis of newly diagnosed advanced ovarian cancer in South Korea
Presenter: Soo Young Jeong
Session: e-Poster Display Session
253P - Non-Epithelial Tumours of Ovary, An Experience from Qatar
Presenter: Ammar Madani
Session: e-Poster Display Session